Edward Tobey, MD
Psychiatry · Texarkana, TXNPI 1306846712
Payments from drug & device makers
Across 543 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$606
- Vanda Pharmaceuticals Inc.$495
- Teva Pharmaceuticals USA, Inc.$386
- Takeda Pharmaceuticals U.S.A., Inc.$324
- plus $2K from 23 others
What the payments were for
- Food & beverage$8,51599%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 225 | $3,074 |
| Otsuka America Pharmaceutical, Inc. | 81 | $1,447 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $606 |
| Vanda Pharmaceuticals Inc. | 31 | $495 |
| Teva Pharmaceuticals USA, Inc. | 22 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $324 |
| Axsome Therapeutics, Inc. | 13 | $267 |
| Lundbeck LLC | 13 | $252 |
| Harmony Biosciences LLC | 9 | $241 |
| Sunovion Pharmaceuticals Inc. | 20 | $239 |
| Neurocrine Biosciences, Inc. | 10 | $200 |
| Johnson & Johnson | 12 | $193 |
| E.r. Squibb & Sons, L.L.C. | 7 | $151 |
| Idorsia Pharmaceuticals US Inc | 6 | $124 |
| Merck | 7 | $94 |
| Corium, LLC | 3 | $73 |
| Supernus Pharmaceuticals, Inc. | 4 | $66 |
| Almatica Pharma LLC | 3 | $55 |
| Alkermes, Inc. | 3 | $48 |
| Eisai Inc. | 3 | $46 |
| Tris Pharma Inc | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Bausch Health US, LLC | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $16 |
| Indivior Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$8,592 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 24 | $265,987 |
| RexultiBrexpiprazole | 91 | $146,412 |
| VraylarCariprazine Hcl | 72 | $104,167 |
| Invega SustennaPaliperidone Palmitate | 35 | $73,366 |
| NuedextaDextromethorphan Hbr/Quinidine | 27 | $46,365 |
| CaplytaLumateperone Tosylate | 20 | $31,806 |
| TrintellixVortioxetine Hydrobromide | 37 | $24,437 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,860 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $16,262 |
| Lurasidone Hcl | 45 | $12,087 |
| Paliperidone ErPaliperidone | 44 | $11,875 |
| Protriptyline Hcl | 44 | $10,471 |
| Clozapine | 222 | $8,646 |
| BelsomraSuvorexant | 16 | $6,747 |
| Duloxetine Hcl | 342 | $6,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $386 | $265,98724 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,447 | $146,41291 claims |
| AbbVieVraylar | $3,074 | $104,16772 claims |
| Johnson & JohnsonInvega Sustenna | $193 | $73,36635 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $28 | $46,36527 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $606 | $31,80620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $324 | $28,51448 claims |
| Alkermes, Inc.Lybalvi | $48 | $18,86012 claims |
| Axsome Therapeutics, Inc.Auvelity | $267 | $16,26213 claims |
| MerckBelsomra | $94 | $6,74716 claims |
| Eisai Inc.Dayvigo | $46 | $5,59715 claims |
| Lilly USA, LLCOlanzapine | $16 | $1,99198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Texarkana
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.